Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911639 | 1.00 | CTSK (0.43) | CTSKTACR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16493531 | 1.00 | CTSK (0.43) | CTSKTACR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4910750 | 0.85 | CTSK (0.42) | CTSKTACR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4910738 | 0.85 | CTSK (0.42) | CTSKTACR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1401049 | 0.85 | CTSK (0.46) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL1401046 | 0.85 | CTSK (0.46) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL4902813 | 0.77 | L3MBTL1 (0.37) | TACR1CYP1A2L3MBTL1 | |
| SCHEMBL27640544 | 0.76 | CTSK (0.57) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL1401278 | 0.76 | CTSK (0.57) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| Hydrochloric Acid SCHEMBL4902819 | 0.76 | L3MBTL1 (0.36) | TACR1CYP1A2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033033-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. | 2008-02-07 | — | — | US | disclosed |
| US-7256211-B1 | 8-azaprostaglandin derivatives and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| EP-1586564-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICINAL USES THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033033-A1 | 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICAL USE THEREOF | HPGDS, PTGIS, PTGER4 | CTSK 903/4885TACR1 1737/4885CYP1A2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.